Rhythm Pharmaceuticals/$RYTM
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Rhythm Pharmaceuticals
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.
Ticker
$RYTM
Sector
Primary listing
Employees
283
Headquarters
Website
RYTM Metrics
BasicAdvanced
$7B
-
-$3.02
2.39
-
Price and volume
Market cap
$7B
Beta
2.39
52-week high
$106.84
52-week low
$45.91
Average daily volume
615K
Financial strength
Current ratio
2.786
Quick ratio
2.45
Long term debt to equity
82.117
Total debt to equity
85.327
Interest coverage (TTM)
-7.90%
Profitability
EBITDA (TTM)
-175.91
Gross margin (TTM)
89.25%
Net profit margin (TTM)
-117.16%
Operating margin (TTM)
-113.53%
Effective tax rate (TTM)
0.01%
Revenue per employee (TTM)
$550,000
Management effectiveness
Return on assets (TTM)
-29.39%
Return on equity (TTM)
-116.97%
Valuation
Price to revenue (TTM)
41.998
Price to book
-564.64
Price to tangible book (TTM)
-380.84
Price to free cash flow (TTM)
-60.65
Free cash flow yield (TTM)
-1.65%
Free cash flow per share (TTM)
-1.735
Growth
Revenue change (TTM)
53.55%
Earnings per share change (TTM)
-31.00%
3-year revenue growth (CAGR)
126.73%
3-year earnings per share growth (CAGR)
-4.73%
10-year earnings per share growth (CAGR)
27.01%
What the Analysts think about RYTM
Analyst ratings (Buy, Hold, Sell) for Rhythm Pharmaceuticals stock.
Bulls say / Bears say
Net product revenue from global IMCIVREE sales reached $48.5 million in Q2 2025, a 29% sequential increase from Q1, demonstrating strong commercial momentum (GlobeNewswire)
The pivotal Phase 3 TRANSCEND trial for setmelanotide met its primary endpoint with a placebo-adjusted 19.8% BMI reduction in patients with acquired hypothalamic obesity, supporting expansion into this indication (GlobeNewswire)
The Phase 2 trial of oral MC4R agonist bivamelagon met its primary endpoint with statistically significant, clinically meaningful BMI reductions, potentially extending Rhythm’s MC4R agonist franchise beyond IMCIVREE (GlobeNewswire)
Inventory fluctuations at the specialty pharmacy led to a $7.2 million net decrease in U.S. product revenue in Q1 2025 compared to Q4 2024, highlighting volatility in reported sales (GlobeNewswire)
Rhythm remains highly dependent on IMCIVREE as its sole commercial product, with epidemiology estimates suggesting only ~29,000 U.S. patients for key genetic indications, limiting near-term addressable market growth (SEC Filing)
GAAP net loss per share widened to ($0.75) in Q2 2025, driven by increased R&D and SG&A expenses, underscoring ongoing unprofitability despite revenue gains (Nasdaq)
Data summarised monthly by Lightyear AI. Last updated on 4 Oct 2025.
RYTM Financial Performance
Revenues and expenses
RYTM Earnings Performance
Company profitability
RYTM News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Rhythm Pharmaceuticals stock?
Rhythm Pharmaceuticals (RYTM) has a market cap of $7B as of October 15, 2025.
What is the P/E ratio for Rhythm Pharmaceuticals stock?
The price to earnings (P/E) ratio for Rhythm Pharmaceuticals (RYTM) stock is 0 as of October 15, 2025.
Does Rhythm Pharmaceuticals stock pay dividends?
No, Rhythm Pharmaceuticals (RYTM) stock does not pay dividends to its shareholders as of October 15, 2025.
When is the next Rhythm Pharmaceuticals dividend payment date?
Rhythm Pharmaceuticals (RYTM) stock does not pay dividends to its shareholders.
What is the beta indicator for Rhythm Pharmaceuticals?
Rhythm Pharmaceuticals (RYTM) has a beta rating of 2.39. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.